anti-PD-L1 (human), mAb (AG-IHC411)
Code | Size | Price |
---|
AG-20B-6022-R100 | 100 ul | £170.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Shipping:
Blue Ice (not freeze)
Storage:
+4°C
Images
Further Information
Alternate Names/Synonyms:
PD-L1; Programmed Death Ligand 1; PDCD1 Ligand 1; CD274; B7-H1; B7 Homolog 1
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In Tris Buffer, pH 7.4, containing 1% BSA and <0.1% sodium azide.
Handling Advice:
Do not freeze.
Immunogen:
Recombinant human PD-L1.
Long Description:
Monoclonal Antibody. Recognizes human PD-L1 (CD274). Applications: ELISA, IHC. Isotype: Rabbit IgG. Clone: AG-IHC411. Liquid. In Tris Buffer, pH 7.4, containing 1% BSA and <0.1% sodium azide. Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. PD-L1 is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. PD-L1 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer and sentinel lymph node melanoma.
This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).
NCBI, Uniprot Number:
Q9NZQ7
Package Type:
Plastic Vial
Product Description:
Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. PD-L1 is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. PD-L1 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer and sentinel lymph node melanoma. This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).
Purity:
Protein A/G purified.
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes human PD-L1 (CD274).
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
Related Products
Product Name | Product Code | Supplier | anti-CD274 [B7-H1] (human), mAb (ANC6H1) | ANC-274-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
anti-CD274 [B7-H1] (human), mAb (ANC6H1) (Biotin) | ANC-274-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD274 [B7-H1/PD-L1] (human), mAb (ANC6H1) (FITC) | ANC-274-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD274 [B7-H1/PD-L1] (human), mAb (ANC6H1) (R-PE) | ANC-274-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD274 [B7-H1] (human), mAb (ANC6H1) (preservative free) | ANC-274-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD274 [B7-H1] (human)-muIg Fusion Protein | ANC-541-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD274 [B7-H1] (human)-muIg Fusion Protein (Biotin) | ANC-541-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD274 [B7-H1] (human)-muIg Fusion Protein (preservative free) | ANC-541-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||